Completed PHASE4 INTERVENTIONAL 2-arm NCT04993365

Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)

A Randomized and Controlled Ⅳ Clinical Trial to Evaluate the Immunogenicity and Safety of COVID-19 Vaccine (Vero Cell), Inactivated Co-administrated With EV71 Vaccine (Vero Cell) in Children Aged 3-5 Years Old

Sponsor: Sinovac Research and Development Co., Ltd.

Conditions COVID-19

Interventions Control Group Experimental Group

Updated 5 times since 2021 Last updated: Oct 7, 2023 Started: Nov 5, 2021 Primary completion: Jul 14, 2022 Completion: Jul 14, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates COVID-19 and is currently completed. Sinovac Research and Development Co., Ltd. leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Nov 2023 — Jul 2024 [monthly]

Completed PHASE4

Status: Suspended → Completed
Sep 2022 — Nov 2023 [monthly]

Suspended PHASE4

Status: Not Yet Recruiting → Suspended
Sep 2021 — Sep 2022 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sinovac Research and Development Co., Ltd.

Data source: Sinovac Biotech Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Yangchun, China
• Zhanjiang, China